The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

Mergers & AcquisitionsMediumUpdated×4•Originally published 27 April 2026•Updated 27 April 2026•

1 min read

Sun Pharma to Acquire Organon in $11.75 Billion All-Cash Deal

Key Facts

1Sun Pharma agreed to acquire all outstanding shares of Organon for $14.00 per share.

2The all-cash deal values the U.S. drugmaker at an enterprise valuation of approximately $11.75 billion.

Sun Pharmaceutical Industries Limited has entered into a definitive agreement to acquire Organon & Co. in an all-cash transaction valued at $11.75 billion, offering $14.00 per share. Market reaction was exceptionally bullish as OGN shares closed at $13.16, marking a 16.87% increase with a massive trading volume of 134 million shares. During the session, the stock hit a new 52-week high, trading within a daily range of $13.15 to $13.24. This acquisition is set to propel Sun Pharma into the ranks of the top 25 global pharmaceutical companies, with combined revenues of approximately $12.4 billion. Furthermore, the deal positions the company as a top-10 global player in the high-growth biosimilars sector. As one of the largest healthcare M&A deals this year, it significantly expands Sun Pharma's strategic footprint in the United States.

about 1 month ago

Version History

4 additional sources confirmed this story

Version 4about 1 month ago

What changed: Updated the story with closing price data, specific percentage gains, significant trading volume metrics, and the achievement of a new 52-week high.

Version 3about 1 month ago

What changed: Added the specific 16% increase in OGN premarket trading and included the stock ticker.

Version 2about 1 month ago

What changed: Updated the story to reflect the positive market reaction and the significant surge in Organon's stock price following the acquisition announcement.

Version 1about 1 month ago

What changed: Added the expected deal closure timeline (early 2027), projected combined revenue figures ($12.4 billion), and strategic ranking targets in the biosimilars market.